| Body System |
Desvenlafaxine |
Placebo |
| |
300 mg
(n=9) |
450 mg
(n=9) |
600 mg
(n=9) |
(n=9) |
| Any adverse event |
8 (89) |
9 (100) |
9 (100) |
9 (100) |
Body as a whole
Asthenia
Headache |
0
1 (11) |
1 (11)
4 (44) |
4 (44)
0 |
0
2 (22) |
Cardiovascular
Hypertension
Postural hypotension
Tachycardia
Tachycardia sinus
Vasodilation
Ventricular extrasystoles |
5 (56)
0
2 (22)
0
0
0 |
8 (89)
0
4 (44)
2 (22)
2 (22)
1 (11) |
8 (89)
6 (67)
9 (100)
0
1 (11)
2 (22) |
1 (11)
0
3 (33)
0
0
0 |
Digestive
Anorexia
Constipation
Nausea
Vomiting |
0
2 (22)
4 (44)
0 |
0
3 (33)
6 (67)
2 (22) |
4 (44)
4 (44)
7 (78)
2 (22) |
0
0
1 (11)
0 |
Metabolic and nutritional
CPK increased
ALT increased |
2 (22)
0 |
0
2 (22) |
0
0 |
1 (11)
1 (11) |
Nervous
Abnormal dreams
Anxiety
Depersonalization
Dizziness
Euphoria
Insomnia
Nervousness
Tremor
Trismus
Twitching |
0
1 (11)
0
2 (22)
0
1 (11)
0
0
0
1 (11) |
0
0
0
1 (11)
0
0
0
0
0
0 |
4 (44)
2 (22)
2 (22)
3 (33)
3 (33)
2 (22)
2 (22)
2 (22)
2 (22)
3 (33) |
0
0
0
0
0
0
0
0
0
0 |
Respiratory
Rhinitis |
0 |
0 |
0 |
2 (22) |
Skin/appendages
Application site reaction
Sweating |
0
0 |
0
0 |
5 (56)
2 (22) |
4 (44)
0 |
Urogenital
Dysuria
Impotence |
0
0 |
0
0 |
2 (22)
2 (22) |
0
0 |
ALT, alanine aminotransferase; CPK, creatine phosphokinase